Published • loading... • Updated
Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
The pill also cut AHI events and helped 31.5% of patients reach remission or mild OSA, Lilly said.
- On Monday, Eli Lilly and Company announced positive Phase 3 ATTAIN-OSA trial results showing its obesity pill, Foundayo, reduced the severity of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight.
- Obstructive sleep apnea affects an estimated 936 million adults worldwide, causing repeated breathing interruptions and oxygen drops linked to serious cardiovascular risks including heart failure and stroke.
- Foundayo reduced breathing interruptions by 43.8% in participants not using positive airway pressure therapy and 27.5% in those using PAP. The drug also lowered sleep apnea-specific hypoxic burden by up to 55.9%.
- Lilly plans to submit Foundayo to the U.S. Food and Drug Administration for approval to treat moderate-to-severe obstructive sleep apnea by the end of 2026.
- Participants taking Foundayo lost an average of 11.5% of their body weight and demonstrated improved cardiovascular risk factors, including reduced systolic blood pressure and lower inflammation markers.
Insights by Ground AI
11 Articles
11 Articles
Eli Lilly's oral drug Foundayo significantly reduced the number of nocturnal breathing pauses in a recent clinical trial, successfully meeting the primary endpoint of a late-stage study in obese adults with moderate to severe obstructive sleep apnea.
·Budapest, Hungary
Read Full Article
Coverage Details
Total News Sources11
Leaning Left0Leaning Right0Center7Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
